Catabasis Pharmaceuticals, Inc. (CATB) - Get Catabasis Pharmaceuticals Inc Report, a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET.
A webcast of the presentation will be available on the investors section of the Company's website, www.catabasis.com, and will be archived for 30 days following the presentation.
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005081/en/